Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
September 08 2021 - 8:30AM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic
medicines company committed to delivering life-changing treatments
for people battling devastating diseases, today announced it will
highlight its ADAR-mediated RNA editing capability, including an
update on its discovery-stage alpha-1 antitrypsin deficiency
(“AATD”) program, as well as its preclinical neurology portfolio
and PRISMTM platform advancements at its 2021 Analyst and Investor
Research Webcast taking place Tuesday, September 28, 2021 at 10:00
a.m. EDT.
The Research Webcast will feature presentations from Wave
management and also review data being presented at the TIDES USA:
Oligonucleotides & Peptide Therapeutics meeting and the 17th
Annual Meeting of the Oligonucleotide Therapeutics Society (OTS),
taking place September 20-23, 2021 and September 26-29, 2021,
respectively. Additional details on the upcoming presentations at
TIDES and OTS can be found by visiting this link.
A link to register for the upcoming Analyst and Investor
Research Webcast event is available here. A live webcast of the
event will be available on the investor relations page of
the Wave Life Sciences corporate website at
http://ir.wavelifesciences.com. A replay of the event will also be
archived and available on the site for a limited time following the
event.
About PRISM™PRISM is Wave Life Sciences’
proprietary discovery and drug development platform that enables
genetically defined diseases to be targeted with stereopure
oligonucleotides across multiple therapeutic modalities, including
silencing, splicing and editing. PRISM combines the company’s
unique ability to construct stereopure oligonucleotides with a deep
understanding of how the interplay among oligonucleotide sequence,
chemistry and backbone stereochemistry impacts key pharmacological
properties. By exploring these interactions through iterative
analysis of in vitro and in vivo outcomes and machine
learning-driven predictive modeling, the company continues to
define design principles that are deployed across programs to
rapidly develop and manufacture clinical candidates that meet
pre-defined product profiles.
About Wave Life SciencesWave Life Sciences
(Nasdaq: WVE) is a clinical-stage genetic medicines company
committed to delivering life-changing treatments for people
battling devastating diseases. Wave aspires to develop
best-in-class medicines across multiple therapeutic modalities
using PRISM, the company’s proprietary discovery and drug
development platform that enables the precise design, optimization,
and production of stereopure oligonucleotides. Driven by a resolute
sense of urgency, the Wave team is targeting a broad range of
genetically defined diseases so that patients and families may
realize a brighter future. To find out more, please visit
www.wavelifesciences.com and follow Wave on Twitter
@WaveLifeSci.
Investor Contact:Kate
Rausch617-949-4827krausch@wavelifesci.com
Media Contact:Alicia
Suter617-949-4817asuter@wavelifesci.com
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Apr 2023 to Apr 2024